
Celularity (CELU) Stock Forecast & Price Target
Celularity (CELU) Analyst Ratings
Bulls say
Celularity Inc is positioned favorably due to its innovative offerings in placental-derived cell therapies, with significant promise demonstrated through clinical efficacy in wound healing, particularly with its product PDA-002, which showed superior ulcer closure rates compared to FDA-approved products. The company's bio-banking segment, which contributes the majority of its revenue, underlines a strong business foundation that supports its research and development activities across other therapeutic areas like cancer and immunologic diseases. Additionally, the successful demonstration of improved structural integrity and handleability in soft tissue repair reinforces Celularity's potential competitiveness in the biotechnology sector, providing a compelling outlook for investors.
Bears say
Celularity Inc faces significant operational risks that may adversely impact its clinical trials, particularly due to potential manufacturing failures, which could hinder both its bio-banking and degenerative diseases sectors. Additionally, the effectiveness of its NK cell therapies is compromised by a natural decline in NK cell function with age, leading to decreased efficacy in older populations, which represents a critical target demographic for its treatments. These fundamental challenges in maintaining operational integrity and addressing efficacy in an aging patient base contribute to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Celularity and is not a guaranteed prediction by Public.com or investment advice.
Celularity (CELU) Analyst Forecast & Price Prediction
Start investing in Celularity (CELU)
Order type
Buy in
Order amount
Est. shares
0 shares